A discussion with Rich Valdés on Dr. Fauci’s testimony before the House Committee on Covid Origins

Dr. Quay speaks at timestamp 46:42

The recent House Committee testimony has stirred up discussions regarding public health, vaccination, and trust in government agencies. Dr. Quay breaks down Dr. Fuaci’s testimony with Rich Valdés on this 2 hour podcast. If you want to hear Dr. Quay’s breakdown fast forward to around the 46 minute mark where the conversation delves into ethical considerations surrounding government-funded research and pharmaceutical pricing. Dr. Quay raised concerns about conflicts of interest and emphasized the need for transparency in these matters.

The discussion also touched upon the contentious issue of gain-of-function research funding by the NIH, with Dr. Quay highlighting regulatory loopholes and the need for accountability.

Ultimately, Dr. Quay stressed the importance of individualized healthcare decisions and the preservation of the patient-provider relationship as the cornerstone of public health. The ongoing challenges underscore the need for transparency, accountability, and a renewed focus on building trust between the public and healthcare institutions.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies